Actively Recruiting
Serum Estradiol (E2) Levels in Breast Cancer Patients During Endocrine Therapy by High Performance Liquid Chromatography-tandem Mass Spectrometry (LC-MS /MS)
Led by Sun Yat-sen University · Updated on 2024-01-09
2000
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators intend to conduct a prospective cohort study to detect E2 levels during endocrine therapy in Chinese breast cancer patients using LC-MS/MS methods, and to determine the proportion of patients with premenopausal E2 levels (OFR or E2 insufficiency) during AIs or FUL endocrine therapy. To further explore the correlation between serum E2 levels and the efficacy of endocrine therapy in Chinese patients, so as to ensure the safety and efficacy of endocrine therapy for patients, and pave the way for further providing more accurate individualized treatment programs.
CONDITIONS
Official Title
Serum Estradiol (E2) Levels in Breast Cancer Patients During Endocrine Therapy by High Performance Liquid Chromatography-tandem Mass Spectrometry (LC-MS /MS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 18 years old
- Histologically confirmed breast cancer
- Early breast cancer patients (with natural or artificial menopause using LHRHa) or advanced breast cancer patients (with natural or artificial menopause using LHRHa) using AIs (letrozole, anastrozole, or exemestane) as adjuvant endocrine therapy
- Patients receiving first-line CDK4/6 inhibitors (Palbociclib, Dalpiciclib, Abemaciclib, or Ribociclib) combined with AI therapy
- Patients receiving second-line CDK4/6 inhibitors combined with fulvestrant (FUL) endocrine therapy
- Patients needing hormone testing
- Patients with standard treatment and complete clinical data, including full efficacy evaluation and follow-up data
You will not qualify if you...
- Breast cancer patients using Tamoxifen (TAM) endocrine therapy
- Advanced patients who have exceeded first-line use of AIs (one endocrine therapy regimen used and failed)
- Advanced patients who have exceeded second-line use of fulvestrant (more than one endocrine therapy regimen used and failed)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
C
Cong Xue, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here